Immune Thrombocytopenia: Expert Guidance to Integrate Emerging Therapies into Clinical Practice

Immune Thrombocytopenia: Expert Guidance to Integrate Emerging Therapies into Clinical Practice

Wednesday, August 17, 2022 in Chicago, Illinois
Dinner -- Sheraton Grand Chicago, 6:20 PM CT
TBD

Agenda

  • Case Discussion 1: Initial Management of ITP (Diagnosis and Treatment Considerations)
    • Evidence-based practice guidelines
    • Standard first-line therapy, optimizing corticosteroids, and strategies to improve the rate of remission
    • Treating ITP in special patient populations
  • Case Discussion 2: Choosing Between Various Second-Line Treatments for ITP
    • Applying guidelines to clinical practice in the second-line management of ITP; personalizing care
    • Treatment of thrombocytopenia in patients with chronic liver disease, those undergoing a planned surgical procedure or those receiving chemotherapy
  • Treatment Approach When Standard Second Line Therapy Fails: Novel and Emerging Therapies Under Development for ITP
  • 2022 Clinical Algorithm for the Management of ITP
  • Audience Question and Answer Session

Faculty

Program Director
David J. Kuter, MD, DPhil

Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Chief of Hematology
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

Faculty
Catherine M. Broome, MD

Associate Professor of Medicine
Lombardi Cancer Center
MedStar Georgetown University
Washington, DC

Faculty
Cindy Neunert, MD, MSCS

Associate Professor
Pediatrics, Hematology/Oncology, Stem Cell Transplant
Columbia University Irving Medical Center
New York, New York

Program Overview
This program will provide expert perspectives on how to integrate established and emerging therapies into the clinical management of immune thrombocytopenia (ITP), including upfront treatment of ITP, strategies for the optimal selection and sequencing of therapies, and considerations for treating ITP in special patient populations, using clinical case studies to illustrate how to utilize personalized medicine approaches.

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners in using new and emerging therapeutic options for patients with immune thrombocytopenia.

Target Audience
This program is intended for hematologists and other healthcare professionals who care for patients with ITP.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify newly diagnosed patients with ITP who would benefit from intensified therapy to improve remission rates
  • Select optimal second or subsequent lines of therapy for patients with ITP who have had an insufficient response to corticosteroids, immunoglobulins, splenectomy, and/or a thrombopoietin receptor agonist
  • Plan therapeutic strategies to manage thrombocytopenia in special populations of patients, including children, pregnant women, those with COVID-19, chronic liver disease, undergoing a planned medical procedure, or receiving chemotherapy
  • Evaluate new clinical trial data and the clinical practice implications of novel targeted therapies in patients with immune thrombocytopenia
  • Discuss ongoing clinical trials investigating novel targeted therapies and combination regimens for the treatment of immune thrombocytopenia

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.